Table 1.
Demographics and clinical characteristics of all randomised patients.
| Docetaxel + capecitabine | Paclitaxel + capecitabine | |
|---|---|---|
| Median age (years) | 52 (35–65) | 53 (41–73) |
| Median weight (kg) | 65 | 64.5 |
| Median height (cm) | 165 | 168.5 |
| Median BSA (m2) | 1.71 | 1.71 |
| Performance status (ECOG) | ||
| 0 | 8 | 12 |
| I | 11 | 5 |
| II | 0 | 1 |
| Estrogen receptor positive | 12/19 | 12/18 |
| Progesterone receptor positive | 10/19 | 6/18 |
| Prior postoperative radiotherapy | 9/19 | 14/18 |
| Prior radiotherapy for metastatic disease | 7/19 | 2/18 |
| Prior adjuvant chemotherapy | 12/19 | 7/18 |
| Prior chemotherapy for metastatic disease | 12/19 | 11/18 |
| Prior endocrine therapy for metastatic disease | 14/19 | 12/18 |
| Metastatic site | ||
| Liver | 7/19 | 9/18 |
| Lung | 5/19 | 7/18 |
| Bone | 6/19 | 10/18 |
| >2 metastatic sites | 4/19 | 1/18 |
| Diabetes | 2/19 | 0/18 |
| Thromboembolism | 0/19 | 1/18 |
| Cardiovascular disease | 0/19 | 1/18 |
| Time from diagnosis to first recurrence (months) (CI) | 55 (20–89) | 33 (16–50) |